Arming antibodies: prospects and challenges for immunoconjugates

By A. Wu, P. Senter. Nature Biotechnology, 2005

1,064 citations recorded by the source corpus.

Subfields: Oncology, Radiology, Nuclear Medicine and Imaging

View Paper: https://www.semanticscholar.org/paper/ac272c404469a492c79dd6ab0fa8d51ca75a1de5

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Oncology

1. Lloyd J. Old
2. M. Sliwkowski
3. Ralph Weissleder
4. Paul Polakis
5. P. Carter
6. J. Wolchok
7. M. Lacouture

In Radiology, Nuclear Medicine and Imaging

1. Paul Polakis
2. H. Raab
3. S. Bhakta
4. Jagath R Junutula
5. S. Panowski
6. M. Sliwkowski
7. Ralph Weissleder
8. P. Carter

Citations in the corpus

• Site-specific antibody drug conjugates for cancer therapy (2013, background): “Therefore, greater than one million different ADC species can be generated.(6,39-41) Cysteine conjugation occurs after reduction of four inter-chain disulfide bonds, and the conjugation is thus limited to the eight exposed sulfhydryl groups.”
• Potent antibody therapeutics by design (2006, background): “For imaging applications, more efficient penetration of tumours and faster clearance from the body are potential advantages of using antibody fragments instead of IgG, because these properties can give rise to improved tumour-to-non-tumour binding ratio”
• Conjugation site modulates the in vivo stability and therapeutic activity of antibody-drug conjugates (2012, background): “and by selecting the appropriate antibody and payloa”
• Antibody therapy of cancer (2012, background): “Essential preclinical characterization includes identification of the physical and chemical properties of the antibody; detailed specificity analysis of antigen expression using panels of normal and malignant tissues; study of the immune effector functions and signalling pathway effects of the antib”
• Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic index (2008, background): “In principle, selective delivery of cytotoxic agents should reduce the systemic toxicity associated with traditional small-molecule chemotherapeutic”
• Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate. (2008, background): “www.aacrjournals.org 9287 Cancer Res 2008; 68: ( 22 ).”
• Tetrazine-Based Cycloadditions: Application to Pretargeted Live Cell Imaging (2008, background): “couples to the remaining antibody, drastically reducing background (21).”
• RosettaAntibodyDesign (RAbD): A general framework for computational antibody design (2017, neutral): “companies, government, and academia[1-7].”